Gene's role in malaria drug resistance proved

In research supported by the National Institute of Allergy and Infectious Diseases (NIAID), David A. Fidock, Ph.D., has proved conclusively that the malaria-causing parasite Plasmodium falciparum became resistant to the anti-malarial drug chloroquine through mutations in a single parasite gene. Paradoxically, this gene acts as both a shield and a chink in the armor of P. falciparum by making the parasite less susceptible to chloroquine, but more susceptible to some other anti-malarials. Dr. Fidock and members of his laboratory at the Albert Einstein College of Medicine published their findings in this week's edition of the journal Science as part of a special issue that also includes publication of the genetic sequence of Anopheles gambiae, a mosquito that transmits malaria.

Chloroquine helped control or eliminate malaria throughout much of the world when it became widely used in the years following World War II. Chloroquine-resistant (CQR) P. falciparum emerged in Southeast Asia and South America in the 1950s and spread through much of Africa within two decades. Compared with chloroquine, drugs to treat CQR malaria are more expensive and cause more side effects while working less effectively. Resurgent malaria brings death and suffering to hundreds of millions and seriously impedes economic growth throughout malarious regions.

"Dr. Fidock's work provides direct and conclusive evidence of what was formerly only suspected; namely, that mutations in a single gene give P. falciparum the ability to resist chloroquine," says Michael Gottlieb, Ph.D., chief of NIAID's parasitology and international programs branch. "Curiously, the presence of this gene, named pfcrt, also appears to make P. falciparum more susceptible to two other anti-malarial drugs, artemisinin and quinine," he adds.

The gene finding has potentially important implications for malaria treatment and control, notes Dr. Gottlieb. "If we can develop further the methods we h

Contact: Anne A. Oplinger
NIH/National Institute of Allergy and Infectious Diseases

Page: 1 2

Related biology news :

1. Master of antimalarial resistance
2. Improved nutrition could reduce malaria burden worldwide
3. Antimalarial substances found in New Caledonian sponges
4. Inadequate vaccines can help breed more vicious malaria strains
5. Discovery in parasite movement may offer insights into malaria
6. Plant-like enzyme acts as key life cycle switch in malaria parasite
7. First target for childhood malaria vaccine
8. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
9. Mosquitoes vs. malaria: How we can win the fight
10. New, non-radioactive screen for antimalarial compounds
11. New advance to combat antibiotic-resistant pneumonia and malaria

Post Your Comments:

(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... solutions for biopharmaceutical R&D, today announced that it has entered into a ... multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions its platform ... Biologics since its formation in 2016, the company is relaunching itself under the Ardent ... its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this ... around the globe, requiring fast track capacity to provide patients with urgently needed ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and monitoring ... did not take off as quickly as people initially expected, and where eSource is ... data electronically for clinical trials and then repurposing it for downstream analysis, at a ...
Breaking Biology Technology:
Cached News: